Forgot Password?
Return to Course Listing

CME: Renal cell carcinoma (RCC): Highlights from the 2015 American Society of Clinical Oncology: Take-Aways, Emerging Practice Changes, and Barriers to their Implementation

Activity Description / Statement of Need:

In this online CME self-learning program:

 

Renal cell carcinoma (RCC) is a cancer that is borne and takes root in the nephrons and is responsible for the vast majority – 85% – of all renal cancers.  With risk factors that include smoking, obesity, cadmium exposure, older age, and genetics, the five year survival rate of those afflicted with kidney cancer overall is 68%. In part because there are not any clear early symptoms associated with kidney cancer, RCC is discovered predominantly after it has already progressed to advanced stages, with the brain, bones, lungs, and liver serving as some of the most common sites of metastases. RCC’s treatment depends on its stage and size, with surgeryutilized for localized tumors and systemic therapy a mainstay of care for metastatic disease. 

 

RCC has many treatment options, both targeted and non-targeted. The former, including monoclonal antibodies and other forms of immunotherapy, is now a standard of care, although angiogenesis inhibition is also an area of consideration.  Emerging evidence is also suggesting ways in which biomarkers and radiographic indicators of response might shape the course of care.   

 

As evidenced by the frequent updating of professional practice guidelines, standards of care have changed and continue to do so rapidly, particularly in the realms of immuno- and monoclonal therapy. In other words, standards of care continue to change at a pace with which it may be difficult for the healthcare provider to keep track.  The unique targets of action and side effect of therapies, new and old,speak to a need for clinicians to remain up to date about the ramifications of selecting each agent over an alternative in the treatment armamentarium, as does about what degree of response constitutes treatment success.  Because treatment failure is associated with poor outcomes, it is important to select the best initial therapy for each patient.

 

Agenda

 

Epidemiology of and risk factors for RCC

Symptomology and diagnosis of RCC 

Updates in treatment in patients with RCC 

Target Audience:

Healthcare professionals specializing in: hematology, oncology, oncology pharmacy, and those who otherwise commonly care for patients with RCC.


Commercial Support Disclosure: This program is supported by educational grants from Novartis.


Release Date: August 04, 2015 -- Expiration Date: August 03, 2017

Faculty: Maxwell Meng, MD

Agenda

Learning Objectives

By the end of the session the participant will be able to:

  • 1. With respect to non-clear cell histology, summarize the most impactful findings presented at ASCO 2015 relating to RCC and apply them to patient cases, taking into account any relevant barriers to care
  • 2. With respect to immunotherapy, summarize the most impactful findings presented at ASCO 2015 relating to RCC and apply them to patient cases, taking into account any relevant barriers to care
  • 3. With respect to adjuvant, systemic-targeted therapy, summarize the most impactful findings presented at ASCO 2015 relating to RCC and apply them to patient cases, taking into account any relevant barriers to care

Accreditation

ACCREDITATION FOR THIS COURSE HAS EXPIRED. YOU MAY VIEW THE PROGRAM, BUT CME / CE IS NO LONGER AVAILABLE AND NO CERTIFICATE WILL BE ISSUED.

Faculty Disclosure and Resolution of COI

 As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review ScientiaCME.

 

Faculty Disclosure: Maxwell Meng, MD has no relevent financial disclosures. 

 

Disclosures of Educational Planners: Charles Turck, PharmD is an officer and part owner of ScientiaCME, LLC.

 

Commercial Support Disclosure: This program is supported by educational grants from Novartis.

Instructions

  • Read the learning objectives above
  • Take the Pre-Test (optional). Completion of the pre-test will help us evaluate the knowedge gained by participating in this CME activity.
  • View the online activity. You may view this is in more than one session, and may pause or repeat any portion of the presentation if you need to.
  • Take the post-test
  • Complete the activity evaluation and CME registration. A CE certificate will be emailed to you immediately.

Cultural and Linguistic Competence

System Requirements

PC
Windows 7 or above
Internet Explorer 8
*Adobe Acrobat Reader
MAC
Mac OS 10.2.8
Safari or Chrome or Firefox
*Adobe Acrobat Reader
Internet Explorer is not supported on the Macintosh

*Required to view Printable PDF Version


Perform Pre-Test (optional)

Please take a few minutes to participate in the optional pre-test. It will help us measure the knowledge gained by participating in this activity.